EMILY WILLIAMS: Open Payments
NPI 1881790913 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,173 in 91 payments from 16 companies in 2025. Trend: 2023 $1,953 · 2024 $1,964 · 2025 $2,173
Food & beverage: $2,106Education: $67
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 23 | $473 |
| AstraZeneca Pharmaceuticals LP | 16 | $389 |
| Regeneron Healthcare Solutions, Inc. | 15 | $386 |
| GENZYME CORPORATION | 10 | $290 |
| Novartis Pharmaceuticals Corporation | 6 | $130 |
| Genentech USA, Inc. | 4 | $117 |
| CSL Behring | 4 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $46 |
| BioCryst US Sales Co., LLC | 2 | $35 |
Products named: DUPIXENT, TRELEGY ELLIPTA, Xolair, NUCALA, AIRSUPRA, BREZTRI, FASENRA, TEZSPIRE.
Industry payments across TX — which companies pay providers there.
